Cough/Cold Sales Shortfall Has Perrigo Looking To Smoking Cessation
This article was originally published in The Tan Sheet
Executive Summary
Perrigo expects nicotine replacement gum product revenue to compensate in part for lagging winter cough/cold sales in the second half of its fiscal year
You may also be interested in...
Perrigo To Market Generic Commit Lozenge; Agis Buy Helps Build OTC Sales
Perrigo expects to start shipping its private-label equivalents to GSK's Commit nicotine lozenges in early March, the company announced Feb. 2
Perrigo To Market Generic Commit Lozenge; Agis Buy Helps Build OTC Sales
Perrigo expects to start shipping its private-label equivalents to GSK's Commit nicotine lozenges in early March, the company announced Feb. 2
Perrigo To Market Generic Commit Lozenge; Agis Buy Helps Build OTC Sales
Perrigo expects to start shipping its private-label equivalents to GSK's Commit nicotine lozenges in early March, the company announced Feb. 2